The task of this Core is to provide well characterized, high-quality human-derived biospecimens required by the projects and to insure that longitudinal, structured, clinical information related to treatment and outcome is collected from the patient donors of those specimens. The primary substrate for these genetic characterization projects is a unique resource consisting of whole-organ maps that will provide histologic characterization and sufficient DNA and RNA to allow multiple experiments to be done on the same samples. This provides an unprecedented opportunity to cross-validate biologic insights coming from these different experimental platforms, and should provide, by far, the most complete view of urothelial carcinogenesis and progression ever realized. This Core will serve as a model for addressing the difficult problems of cross investigator and cross-institutional data exchange, issues of significant interest for the broader context of Texas cancer research. This Core will provide a web-based portal that will allow all investigators to browse and query the contents of the biorepository, de-identified clinical data, and translational research resources such as Standard Operating Procedures, reagent details, and primary datasets.
The specific aims for the core are as follows:
Specific Aim 1 : Provide pathologic review of all tissues.
Specific Aim 2 : Maintain a urothelial biospecimen repository, Specific Aim 3: Provide professional and technical services for the preparation and quality control of molecular analytes from the biospecimen repository.
Specific Aim 4 : Abstract clinical information for all patients providing biospecimens.
Specific Aim 5 : Capture longitudinal clinical follow-up on all patients providing biospecimens.
Specific Aim 6 : Assure that all information related to the SPORE Project is exchangeable.
Specific Aim 7 : Provide all SPORE Investigators with a common portal for access to Project data, including support for ad hoc query across projects and domains

Public Health Relevance

The projects of this SPORE will use human cancer bladder specimens and human bladder cancer cell lines for translational research directed toward improving the detection, prevention, and treatment of human bladder cancer. The Core will provide the investigators at The University of Texas MD Anderson Cancer Center as well as other collaborating institutions with high quality tissue samples from patients with bladder cancer diagnosed, treated, and followed in our institution. Standardized and centralized procedures have been established for tissue procurement, quality control, processing, storage, and distribution of samples to individual investigators. They will ensure optimal utilization of the samples according to the guidelines established by the Tissue Committee and IRB regulations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA091846-13
Application #
8745036
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
13
Fiscal Year
2014
Total Cost
Indirect Cost
City
Houston
State
TX
Country
United States
Zip Code
77030
Dadhania, Vipulkumar; Zhang, Miao; Zhang, Li et al. (2016) Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine 12:105-117
von Rundstedt, Friedrich-Carl; Mata, Douglas A; Shen, Steven et al. (2016) Transurethral biopsy of the prostatic urethra is associated with final apical margin status at radical cystoprostatectomy. J Clin Urol 9:404-408
McConkey, David J; Choi, Woonyoung; Shen, Yu et al. (2016) A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cis Eur Urol 69:855-62
Kamat, Ashish M; Briggman, Joseph; Urbauer, Diana L et al. (2016) Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin. Eur Urol 69:197-200
Machiela, Mitchell J; Zhou, Weiyin; Karlins, Eric et al. (2016) Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. Nat Commun 7:11843
Figueroa, Jonine D; Middlebrooks, Candace D; Banday, A Rouf et al. (2016) Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Hum Mol Genet 25:1203-14
Kamat, Ashish M; Willis, Daniel L; Dickstein, Rian J et al. (2016) Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJU Int 117:754-60
Sircar, Kanishka; Yoo, Suk-Young; Majewski, Tadeusz et al. (2015) Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. J Pathol Clin Res 1:212-24
Ke, Hung-Lung; Lin, Jie; Ye, Yuanqing et al. (2015) Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation for Non-muscle Invasive Bladder Cancer. Ann Surg Oncol 22:4104-10
(2015) Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. J Natl Cancer Inst 107:djv279

Showing the most recent 10 out of 221 publications